Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    therapeutic vaccine | Open Studies | HIV
Show Display Options
Rank Status Study
21 Not yet recruiting Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients
Condition: HIV Infection
Interventions: Biological: DCV3;   Biological: DCV3 with PEG-INF;   Biological: Placebo;   Biological: Placebo with PEG-INF
22 Recruiting Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
Condition: HIV
Interventions: Drug: triple therapy;   Drug: dual therapy
23 Recruiting Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Condition: Rabies
Intervention: Biological: rabies vaccine
24 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CD34 Stem Cell Selection Therapy
25 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults
Condition: HIV-1
Intervention: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
26 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
27 Recruiting Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-27) Next Page   
Study has passed its completion date and status has not been verified in more than two years.